Tango Therapeutics, Inc. (NasdaqGM: TNGX)
Health Care · Biotechnology · US
$23.61
-1.13% today · +246.1% 1Y
Tango Therapeutics, Inc. (NasdaqGM: TNGX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.03B and employs 137 people.
Over the last twelve months the share price has gained 246.1%, trading between 6.25 and 34.39.
Tweenvest scores Tango Therapeutics, Inc. across four factors: quality 28/100, value 70/100, growth 100/100. Its strongest factor is growth.
TNGX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.03B
- Revenue (TTM)
- $53.81M
- P/E
- —
- EPS
- -0.91
- Dividend yield
- —
- Beta (5Y)
- 1.15
- 52-week high
- $34.39
- 52-week low
- $6.25
- Avg volume (3M)
- —
- Shares outstanding
- 168.61M
- Employees
- 137
- Next earnings
- —
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
- Founded
- 2017
- Listed since
- Sep 3, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.50 | -0.55% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.25 | +0.21% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.32 | -0.55% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.33 | +0.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.06 | -1.08% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $135.44 | -6.64% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.